• ALS News

  Add-on Masitinib Slows Progression of ALS, Phase 2/3 Trial Results Show

  Posted by ALS News Today Moderator on July 24, 2019 at 10:32 am

  

  Masitinib in combination with Rilutek (riluzole) slows functional decline of patients with ALS who have a typical disease progression, trial results show. Read more about the trial and its findings here.

  How do you feel about this news?

  ALS News Today Moderator replied 4 years, 9 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply